Cargando…

Harnessing the epigenome to boost immunotherapy response in non-small cell lung cancer patients

The introduction of immune checkpoint inhibitor (ICI)-based therapy for non-oncogene addicted non-small cell lung cancer (NSCLC) has significantly transformed the treatment landscape of the disease. Inhibitors of the programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) immune check...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gkountakos, Anastasios, Delfino, Pietro, Lawlor, Rita T., Scarpa, Aldo, Corbo, Vincenzo, Bria, Emilio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161860/ https://www.ncbi.nlm.nih.gov/pubmed/34104224 http://dx.doi.org/10.1177/17588359211006947

Ejemplares similares

Chemo-immunotherapy as first-line treatment for small-cell lung cancer
por: Farid, Saira, et al.
Publicado: (2020)

Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC
por: Xuzhang, Wendi, et al.
Publicado: (2023)

Effect of immunotherapy on overall survival in limited-stage small cell lung carcinoma: a national cancer database analysis
por: Bilani, Nadeem, et al.
Publicado: (2021)

Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study
por: Dimitrakopoulos, Foteinos-Ioannis, et al.
Publicado: (2022)

The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
por: Low, Jia Li, et al.
Publicado: (2019)

Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
por: Yamada, Tadaaki, et al.
Publicado: (2020)

A phase II study of atezolizumab for pretreated advanced/recurrent non-small cell lung cancer with idiopathic interstitial pneumonias: rationale and design for the TORG1936/AMBITIOUS study
por: Ikeda, Satoshi, et al.
Publicado: (2020)

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
por: Cinausero, Marika, et al.
Publicado: (2019)

TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer
por: Li, Teng, et al.
Publicado: (2021)

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses
por: Gristina, Valerio, et al.
Publicado: (2021)

A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study)
por: Shibaki, Ryota, et al.
Publicado: (2021)

Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study
por: Zhou, Fei, et al.
Publicado: (2022)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Physical Activity and Exercise in Lung Cancer Care: Will Promises Be Fulfilled?
por: Avancini, Alice, et al.
Publicado: (2019)

Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
por: Carbone, Carmine, et al.
Publicado: (2021)

Distribution and characterization of microplastics in marine sediments from the Montenegrin coast
por: Bošković, Neda, et al.
Publicado: (2022)

Adoptive T Cell Immunotherapy for Cancer
por: Perica, Karlo, et al.
Publicado: (2015)

Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy
por: Hsu, Melinda L, et al.
Publicado: (2022)

The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma
por: Dibajnia, Pooya, et al.
Publicado: (2023)

Update on combined immunotherapy for the treatment of advanced renal cell carcinoma
por: Gebrael, Georges, et al.
Publicado: (2023)

Global research trends on immunotherapy in cancer: A bibliometric analysis
por: Yao, Zhichao, et al.
Publicado: (2023)

Bibliometric analysis on the progress of immunotherapy in renal cell carcinoma from 2003-2022
por: Zhu, Haiyan, et al.
Publicado: (2023)

The impact of COVID-19 on tuberculosis: challenges and opportunities
por: Kant, Surya, et al.
Publicado: (2021)

Bronchial brushing Xpert improves the diagnostic efficiency of sputum Xpert in patients with pulmonary tuberculosis
por: He, Yu, et al.
Publicado: (2021)

The role of bronchoscopy in the diagnosis and management of pediatric pulmonary tuberculosis
por: Goussard, Pierre, et al.
Publicado: (2021)

Development of a nomogram for predicting treatment default under facility-based directly observed therapy short-course in a region with a high tuberculosis burden
por: Wang, Saibin
Publicado: (2021)

Addressing TB-related mortality in adults living with HIV: a review of the challenges and potential solutions
por: Sullivan, Amanda, et al.
Publicado: (2022)

Harnessing neutrophil plasticity for HCC immunotherapy
por: Ramon-Gil, Erik, et al.
Publicado: (2023)

Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study
por: Rossi, Ernesto, et al.
Publicado: (2023)

Cancer immunotherapy: recent advances and challenges
por: Swami, Umang, et al.
Publicado: (2021)

Visual analysis of global research on immunotherapy for gastric cancer: A literature mining from 2012 to 2022
por: Chen, Yizhen, et al.
Publicado: (2023)

Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies
por: Zhao, Dong, et al.
Publicado: (2023)

First-line ICIs in renal cell carcinoma
por: Fiorentino, Vincenzo, et al.
Publicado: (2023)

PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around
por: Gkountakos, Anastasios, et al.
Publicado: (2019)

Global research trends on B7-H3 for cancer immunotherapy: A bibliometric analysis (2012-2022)
por: Huang, Xiaojuan, et al.
Publicado: (2023)

Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report
por: Xie, Xiao-Hong, et al.
Publicado: (2023)

A review of the clinical experience with CMN-001, a tumor RNA loaded dendritic cell immunotherapy for the treatment of metastatic renal cell carcinoma
por: DeBenedette, Mark, et al.
Publicado: (2023)

The dark side of immunotherapy
por: Okwundu, Nwanneka, et al.
Publicado: (2021)

‘Reduced’ HUNT model outperforms NLST and NELSON study criteria in predicting lung cancer in the Danish screening trial
por: Røe, Oluf Dimitri, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_m73ubfhq872tgidoia2o1n70mf